Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 16

1.

Single photon emission computed tomography/positron emission tomography imaging and targeted radionuclide therapy of melanoma: new multimodal fluorinated and iodinated radiotracers.

Maisonial A, Kuhnast B, Papon J, Boisgard R, Bayle M, Vidal A, Auzeloux P, Rbah L, Bonnet-Duquennoy M, Miot-Noirault E, Galmier MJ, Borel M, Askienazy S, Dollé F, Tavitian B, Madelmont JC, Moins N, Chezal JM.

J Med Chem. 2011 Apr 28;54(8):2745-66. doi: 10.1021/jm101574q. Epub 2011 Mar 21.

PMID:
21417462
2.

Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution.

Bonnet M, Mishellany F, Papon J, Cayre A, Penault-Llorca F, Madelmont JC, Miot-Noirault E, Chezal JM, Moins N.

Pigment Cell Melanoma Res. 2010 Oct;23(5):e1-11. doi: 10.1111/j.1755-148X.2010.00716.x. Epub 2010 Apr 22.

PMID:
20444199
3.

Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance.

Greguric I, Taylor SR, Denoyer D, Ballantyne P, Berghofer P, Roselt P, Pham TQ, Mattner F, Bourdier T, Neels OC, Dorow DS, Loc'h C, Hicks RJ, Katsifis A.

J Med Chem. 2009 Sep 10;52(17):5299-302. doi: 10.1021/jm9008423.

PMID:
19691348
4.

Benzamides as melanotropic carriers for radioisotopes, metals, cytotoxic agents and as enzyme inhibitors.

Oltmanns D, Eisenhut M, Mier W, Haberkorn U.

Curr Med Chem. 2009;16(17):2086-94. Review.

PMID:
19519383
5.

Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent.

Bonnet-Duquennoy M, Papon J, Mishellany F, Labarre P, Guerquin-Kern JL, Wu TD, Gardette M, Maublant J, Penault-Llorca F, Miot-Noirault E, Cayre A, Madelmont JC, Chezal JM, Moins N.

Int J Cancer. 2009 Aug 1;125(3):708-16. doi: 10.1002/ijc.24413.

6.

Melanoma affinity in mice and immunosuppressed sheep of [(125)I]N-(4-dipropylaminobutyl)-4-iodobenzamide, a new targeting agent.

Labarre P, Papon J, Rose AH, Guerquin-Kern JL, Morandeau L, Wu TD, Moreau MF, Bayle M, Chezal JM, Croisy A, Madelmont JC, Turner H, Moins N.

Nucl Med Biol. 2008 Oct;35(7):783-91. doi: 10.1016/j.nucmedbio.2008.07.003.

PMID:
18848663
7.

Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.

Desbois N, Gardette M, Papon J, Labarre P, Maisonial A, Auzeloux P, Lartigue C, Bouchon B, Debiton E, Blache Y, Chavignon O, Teulade JC, Maublant J, Madelmont JC, Moins N, Chezal JM.

Bioorg Med Chem. 2008 Aug 15;16(16):7671-90. doi: 10.1016/j.bmc.2008.07.015. Epub 2008 Jul 10.

PMID:
18656367
8.

Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.

Chezal JM, Papon J, Labarre P, Lartigue C, Galmier MJ, Decombat C, Chavignon O, Maublant J, Teulade JC, Madelmont JC, Moins N.

J Med Chem. 2008 Jun 12;51(11):3133-44. doi: 10.1021/jm701424g. Epub 2008 May 16.

PMID:
18481842
9.

Uptake in melanoma cells of N-(2-diethylaminoethyl)-2-iodobenzamide (BZA2), an imaging agent for melanoma staging: relation to pigmentation.

Mansard S, Papon J, Moreau MF, Miot-Noirault E, Labarre P, Bayle M, Veyre A, Madelmont JC, Moins N.

Nucl Med Biol. 2005 Jul;32(5):451-8.

PMID:
15982575
10.

Synthesis, in vitro binding and biodistribution in B16 melanoma-bearing mice of new iodine-125 spermidine benzamide derivatives.

Moreau MF, Papon J, Labarre P, Moins N, Borel M, Bayle M, Bouchon B, Madelmont JC.

Nucl Med Biol. 2005 May;32(4):377-84.

PMID:
15878507
11.

123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging.

Moins N, D'Incan M, Bonafous J, Bacin F, Labarre P, Moreau MF, Mestas D, Noirault E, Chossat F, Berthommier E, Papon J, Bayle M, Souteyrand P, Madelmont JC, Veyre A.

Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1478-84. Epub 2002 Sep 11.

PMID:
12397467
12.

Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent.

Labarre P, Papon J, Moreau MF, Moins N, Bayle M, Veyre A, Madelmont JC.

Melanoma Res. 2002 Apr;12(2):115-21.

PMID:
11930107
13.

Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents.

Moins N, Papon J, Seguin H, Gardette D, Moreau MF, Labarre P, Bayle M, Michelot J, Gramain JC, Madelmont JC, Veyre A.

Nucl Med Biol. 2001 Oct;28(7):799-808.

PMID:
11578901
14.

Distribution of I-BZA (N-2-diethylaminoethyl-4-iodobenzamide) in grafted melanoma and normal skin: a study by secondary ion mass spectroscopy.

Chehade F, De Labriolle-Vaylet C, Michelot J, Moins N, Moreau MF, Hindié E, Papon J, Escaig F, Galle P, Veyre A.

Cell Mol Biol (Noisy-le-grand). 2001 May;47(3):529-34.

PMID:
11441960
15.

Clinical study of [123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma.

Bacin F, Michelot J, Bonafous J, Veyre A, Moreau MF, Kemeny JL, Chossat F, Bekhechi D.

Acta Ophthalmol Scand. 1998 Feb;76(1):56-61.

16.

Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).

Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, Bussiere F, Souteyrand PA, Mauclaire LP, Chossat FM, et al.

J Nucl Med. 1993 Aug;34(8):1260-6.

Supplemental Content

Support Center